Study of Recombinant Factor IX Product, IB1001, in Previously Treated Pediatric Subjects With Hemophilia B

PHASE3TerminatedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

November 30, 2010

Primary Completion Date

December 31, 2016

Study Completion Date

December 31, 2016

Conditions
Hemophilia B
Interventions
BIOLOGICAL

IB1001

Trial Locations (10)

46260

Indiana Hemophilia & Thrombosis Center, Indianapolis

60612

RUSH University Medical Center, Chicago

77030

Gulf States Hemophilia & Thrombophilia Center, Houston

141008

Christian Medical College and Hospital, Ludhiana

390003

Bhailal Amin General Hospital, Vadodara

411001

Jehangir Clinical Development Centre Pvt. Ltd. Jehangir Hospital Premises, Pune

411004

Sahyadri Speciality Hospital, Pune

632004

Christian Medical College, Vellore

700073

AMRI Hospital, Institute of Haematology & Transfusion Medicine, Kolkata

WC1N 3JH

Great Ormond Street Hospital for Children, London

Sponsors
All Listed Sponsors
lead

Medexus Pharma, Inc.

INDUSTRY